896466-67-4

Upstream product

• 109-01-3 1-methyl-piperazine 
• 327056-73-5 3-fluoro-5-chlorobenzonitrile 

Downstream Products

• 1095274-50-2 {5-[3-chloro-5-(4-methyl-1-piperazinyl)phenyl]-1,3,4-oxadiazol-2-yl}acetic acid 
• 1095274-49-9 ethyl {5-[3-chloro-5-(4-methyl-1-piperazinyl)phenyl]-1,3,4-oxadiazol-2-yl}acetate 
• 1095274-48-8 ethyl 3-(2-{[3-chloro-5-(4-methyl-1-piperazinyl)phenyl]carbonyl}hydrazino)-3-oxopropanoate 
• 1095273-37-2 1-[1-({5-[3-chloro-5-(4-methyl-1-piperazinyl)phenyl]-1,3,4-oxadiazol-2-yl}acetyl)-4-piperidinyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1123623-02-8 (E)-3-(3-{(E)-3-[3-chloro-5-(4-methyl-piperazin-1-yl)-phenyl]-3-oxo-propenyl}-phenyl)-N-hydroxy-acrylamide hydrochloride 
• 1123622-45-6 tert-butyl (E)-3-(3-{(E)-3-[3-chloro-5-(4-methyl-piperazin-1-yl)-phenyl]-3-oxo-propenyl}-phenyl)-acrylate 
• 896466-68-5 3-chloro-5-(4-methylpiperazin-1-yl)benzoic acid 
• 952281-84-4 1-[3-chloro-5-(4-methyl-piperazin-1-yl)-phenyl]-ethanone 

Relevant academic research and scientific papers

NURR1 RECEPTOR MODULATORS

Described herein, inter alia, are Nurr1 receptor modulators and uses thereof. In an aspect is provided a method for treating a disease associated with dysregulation and/or degeneration of dopaminergic neurons in the central nervous system of a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein.

A new class of histone deacetylase inhibitors

This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nit

5-PHENYL-1,3,4-OXADIAZOL-2-YL-ACETYL-4-PIPERIDINYL DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The present invention relates to novel compounds that are CGRP receptor antagonists, processes for their preparation, to compositions containing them and to their use in the treatment of migraine, headache, and cluster headache.

PHARMACEUTICAL COMPOUNDS

The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDKl , Chk (e.g. Cbkl or Chk2),

A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS

New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH-NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or

PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES

The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions con